echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: CBRN mutation associated with multiple myeloma to obtain resistance to amines or pomadamine.

    Blood: CBRN mutation associated with multiple myeloma to obtain resistance to amines or pomadamine.

    • Last Update: 2020-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The emergence of resistance to all available treatments is a major challenge in improving survival in myeloma patients.
    Cereblon (CRBN) is a widely used IMiD and new CelMOD drug in myeloma, as well as an essential binding protein for certain PROTACs being developed for a variety of diseases. Using genome-wide sequencing data from 455 patients and RNA sequencing data from 655 patients,
    found that three CRBN variants (i.e., point mutations, copy number loss/structural variation, and special transcription variants (such as exon 10 shear variants) gradually increased in frequency, accompanied by IMiD sexual exposure until about one-third of patients with POM incurability developed.
    researchers found that all three CRBN variants were associated with poor use of POM in patients with LEN retrebility, including previously unexpiced individuals with missing copies and structural variations.
    , it is understood that this study is the first comprehensive analysis of the CBRN mutation in patients with myeloma progressing in treatment, which can help guide patients to choose CRBN targeted drug sequentia therapy.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.